Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center Post published:August 31, 2022 Post category:Press Release
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering Post published:August 31, 2022 Post category:Press Release
Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 Post published:August 30, 2022 Post category:Press Release
Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients Post published:August 30, 2022 Post category:Press Release
PsyBio Therapeutics Reports Second Quarter 2022 Financial Results Post published:August 30, 2022 Post category:Press Release
Wesana Announces Second Quarter 2022 Financial Results Post published:August 30, 2022 Post category:Press Release
Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs Post published:August 29, 2022 Post category:Psychedelic Bulletin
MindMed Completes 1-for-15 Reverse Share Split Post published:August 27, 2022 Post category:Press Release
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Post published:August 26, 2022 Post category:Press Release
Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors Post published:August 25, 2022 Post category:Press Release